Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis

Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer cells, but active-site dual mTORC1 and mTORC2 (mammalian target of rapamy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakaria, Chadi, Sean, Polen, Hoang, Huy-Dung, Leroux, Louis-Phillipe, Watson, Margaret, Workenhe, Samuel Tekeste, Hearnden, Jaclyn, Pearl, Dana, Truong, Vinh Tai, Robichaud, Nathaniel, Yanagiya, Akiko, Tahmasebi, Soroush, Jafarnejad, Seyed Mehdi, Jia, Jian-Jun, Pelin, Adrian, Diallo, Jean-Simon, Le Boeuf, Fabrice, Bell, John Cameron, Mossman, Karen Louise, Graber, Tyson Ernst, Jaramillo, Maritza, Sonenberg, Nahum, Alain, Tommy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124814/
https://www.ncbi.nlm.nih.gov/pubmed/30138450
http://dx.doi.org/10.1371/journal.ppat.1007264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124814/
https://www.ncbi.nlm.nih.gov/pubmed/30138450
http://dx.doi.org/10.1371/journal.ppat.1007264

Ejemplares similares